0

ABOUT US

Board of Directors
Wyle Solomon
Hans T. Schambye
Torsten Goesch
Management
Scientific advisors
Investors
Forward Pharma > about us > board of directors >Hans T. Schambye

Wyle Solomon , MSc, MBA

Chairman


Wyle Solomon joined the Forward Pharma A/S Board of Directors in 2008. Read more.



Hans T. Schambye, MD, PhD

Board member


Hans Schambye is an independent biotech consultant and board member. He currently served as Chairman of the Board for Rose Pharma and Nanoference. Previously, Dr. Schambye served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2005 to 2006. Before joining Gastrotech, Dr. Schambye was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company.
In 1999, Dr. Schambye co-founded ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this Dr. Schambye had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Dr. Schambye holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.



Torsten Goesch, MD, PhD, MBA

Board member


Dr. Torsten Goesch is a director of Rosetta Capital, formerly BioScience Managers Limited (BML) Read more.